Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies
| Autor: | Rahul Bhargava, Prakas Kumar Mandal, Divya Doval, Tuphan Kanti Dolai, Gyanendra Singh, Amrita Chakrabarti, Vipin Khandelwal, Pronamee Borah, Divya Bansal, Aditi Jain, Sumeet Prakash Mirgh, Sanjeev Sharma, Rahul Naithani, Sachin Bansal, Sweta Lunkad, Bilal Kazi, Amit Rauthan, Ashish Dixit, Mallikarjun Kalashetty, Naveen Gupta, Preethi Jeyaraman, Dharma Choudhary, Meet Kumar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Survival Adolescent Remission medicine.medical_treatment India Comorbidity Article 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Epidemiology medicine Humans Young adult Child Molecular Biology Survival analysis Aged Retrospective Studies Aged 80 and over Chemotherapy business.industry Mortality rate Remission Induction Age Factors COVID-19 Retrospective cohort study Cell Biology Hematology Middle Aged medicine.disease Survival Analysis 030104 developmental biology Treatment Outcome Child Preschool Hematologic Neoplasms Cohort Molecular Medicine Female business 030215 immunology |
| Zdroj: | Blood Cells, Molecules, and Diseases Blood Cells, Molecules & Diseases |
| ISSN: | 1079-9796 |
| DOI: | 10.1016/j.bcmd.2020.102525 |
| Popis: | Background There is scarcity of data on outcome of COVID-19 in patients with hematological malignancies. Primary objective of study was to analyse the 14-day and 28-day mortality. Secondary objectives were to correlate age, comorbidities and remission status with outcome. Methods Retrospective multicentre observational study conducted in 11 centres across India. Total 130 patients with hematological malignancies and COVID-19 were enrolled. Results Fever and cough were commonest presentation. Eleven percent patients were incidentally detected. Median age of our cohort was 49.5 years. Most of our patients had a lymphoid malignancy (n = 91). One-half patients (52%) had mild infection, while moderate and severe infections contributed to one-fourth each. Sixty seven patients (52%) needed oxygen For treatment of COVID-19 infection, half(n = 66) received antivirals. Median time to RT-PCR COVID-19 negativity was 17 days (7–49 days). Nearly three-fourth (n = 95) of our patients were on anticancer treatment at time of infection, of which nearly two-third (n = 59;64%) had a delay in chemotherapy. Overall, 20% (n = 26) patients succumbed. 14-day survival and 28-day survival for whole cohort was 85.4% and 80%, respectively. One patient succumbed outside the study period on day 39. Importantly, death rate at 1 month was 50% and 60% in relapse/refractory and severe disease cohorts, respectively. Elderly patients(age ≥ 60) (p = 0.009), and severe COVID-19 infection (p = 0.000) had a poor 14-day survival. The 28-day survival was significantly better for patients in remission (p = 0.04), non-severe infection (p = 0.00), and age Conclusions Elderly patients with hematological malignancy and severe covid-19 have worst outcomes specially when disease is not in remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect